PR3-ANCA n = 67 | MPO-ANCA n = 72 | p | |
---|---|---|---|
Sex, F/M | 24/43 | 36/36 | 0.092 |
Diagnosis: GPA/MPA/EGPA | 42/25/0 | 9/62/1 | |
Age at diagnosis, yrs | 64.8 ± 16.4 | 70.1 ± 14.3 | 0.043 |
Diagnosis delay, mos | 2 (1–3) | 2 (1–4) | 0.206 |
Laboratory results | |||
C-reactive protein, mg/dl | 11.8 (8.8–17.7) | 4.6 (0.9–12.6) | < 0.001 |
ESR, mm/h | 80.1 ± 29.6 | 64.2 ± 36.0 | 0.047 |
Hemoglobin, g/dl | 10.8 ± 1.89 | 10.2 ± 1.68 | 0.05 |
Thrombocyte count, × 109/l | 387 (314–483) | 316 (260–386) | 0.001 |
White blood cell count, × 109/l | 12.5 (10–15) | 9.3 (7.1–12.5) | 0.001 |
Creatinine at diagnosis, mg/dl | 2.64 (1.37–4.10) | 3.05 (1.73–5.77) | 0.062 |
Creatinine at last followup*, mg/dl | 1.19 (0.85–1.60) | 1.39 (1.01–1.84) | 0.187 |
Patients with GFR < 50 ml/min at last followup*, n (%) | 12/35 (34) | 13/27 (48) | 0.243 |
Patients developed ESRD, n (%) | 10 (15) | 27 (38) | 0.003 |
Patients with ≥ 3 organ systems involved, n (%) | 50 (75) | 42 (58) | 0.042 |
Death, n (%) | 29 (43) | 35 (49) | 0.529 |
Organ system involved at diagnosis | |||
General, n (%) | 64 (96) | 60 (83) | 0.021 |
ENT, n (%) | 31 (46) | 9 (13) | < 0.001 |
Chest, n (%) | 32 (48) | 29 (40) | 0.374 |
Nervous, n (%) | 7 (10) | 4 (6) | 0.286 |
Cutaneous, n (%) | 4 (6) | 3 (4) | 0.627 |
Mucocutaneous and eyes, n (%) | 5 (7) | 1 (1) | 0.078 |
Cardiovascular, n (%) | 2 (3) | 3 (4) | 0.709 |
Abdominal, n (%) | 4 (6) | 8 (11) | 0.281 |
Renal histology findings, n (%) | |||
Diffuse crescentic GN, pauciimmune | 15 (22) | 11 (15) | 0.282 |
Diffuse crescentic GN, IF not done | 2 (3) | 3 (4) | 0.585 |
Diffuse crescentic GN, granular IgG/C3 | 1 (1.5) | 2 (3) | 0.602 |
Focal necrotizing/crescentic GN, pauciimmune | 24 (36) | 22 (31) | 0.509 |
Focal necrotizing/crescentic GN, IF not done | 3 (4.5) | 8 (11) | 0.147 |
Pauciimmune small vessel vasculitis without GN | 0 (0) | 3 (4) | 0.091 |
Miscellaneous or insufficient material for diagnosis | 5 (8) | 8 (11) | 0.46 |
No renal biopsy performed | 17 (25) | 15 (21) | 0.525 |
↵* Data on creatinine and GFR < 50 ml/min at last followup (May 2012), included only patients alive and with native kidney function at last followup. All other demographic, clinical, and laboratory data are based on 139 patients with renal involvement. Results are reported as mean ± SD (normally distributed variables) or median and interquartile range (not normally distributed variables), or number and percentage. AAV: ANCA-associated vasculitis; GPA: granulomatosis with polyangiitis (formerly Wegener); MPA: microscopic polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); ESRD: endstage renal disease; ENT: ear-nose-throat; GN: glomerulonephritis; ESR: erythrocyte sedimentation rate; ANCA: anti-neutrophil cytoplasmic antibody; PR3: proteinase 3; MPO: myeloperoxidase; GFR: glomerular filtration rate; IF: immunofluorescence.